usp

SAFETY DATA SHEET

1. Identification

Product identifier Clozapine

Other means of identification

 Catalog number
 1142107

 CAS number
 5786-21-0

Chemical name 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine

Recommended use Specified quality tests and assay use only.

Recommended restrictions Not for use as a drug. Not for administration to humans or animals.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

Company name U. S. Pharmacopeia
Address 12601 Twinbrook Parkway

Rockville MD 20852-1790

United States

Telephone RS Technical Services 301-816-8129

Website www.usp.org
E-mail RSTECH@usp.org

Emergency phone number CHEMTREC within US & 1-800-424-9300

Canada

CHEMTREC outside US & +1 703-527-3887

Canada

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Acute toxicity, oral Category 3

Specific target organ toxicity, single exposure Category 3 narcotic effects

Environmental hazards Not classified.

OSHA defined hazards Not classified.

Label elements



Signal word Danger

Hazard statement Toxic if swallowed. May cause drowsiness or dizziness.

Precautionary statement

Prevention Avoid breathing dust/fume/gas/mist/vapors/spray. Wash thoroughly after handling. Use only

outdoors or in a well-ventilated area.

Response If swallowed: Immediately call a poison center/doctor. Rinse mouth. If inhaled: Remove person to

fresh air and keep comfortable for breathing. Call a poison center/doctor if you feel unwell.

Storage Store in a well-ventilated place. Keep container tightly closed. Store locked up.

Disposal Dispose of contents/container in accordance with local/regional/national/international regulations.

Hazard(s) not otherwiseClassified (HNOC)

This product is supplied in a small quantity which does not constitute a combustible dust hazard.

The physical properties of this material indicate that in large quantities accumulated dust may be

hazardous.

Supplemental information Pharmacologically active material.

Material name: Clozapine usp sps us

1142107 Version #: 05 Revision date: 05-29-2019 Issue date: 06-17-2009

3. Composition/information on ingredients

Substance

Chemical name	Common name and synonyms	CAS number	%
Clozapine		5786-21-0	100

4. First-aid measures

Inhalation If breathing is difficult, remove to fresh air and keep at rest in a position comfortable for breathing.

Call a poison center or doctor/physician if you feel unwell.

Rinse skin with water/shower. Get medical attention if irritation develops and persists. Skin contact

Rinse with water. Get medical attention if irritation develops and persists. Eve contact

Rinse mouth. If ingestion of a large amount does occur, call a poison control center immediately. Ingestion

Do not induce vomiting without advice from poison control center. If vomiting occurs, keep head low so that stomach content doesn't get into the lungs. Do not use mouth-to-mouth method if

substance is ingested.

Most important symptoms/effects, acute and delayed

Pharmacologically active material. Occupational exposure may cause physiological effects.

Indication of immediate medical attention and special treatment needed

Treat symptomatically. Treatment of clozapine overdose may include the following: Establish and maintain a patent airway. Ensure adequate oxygenation and ventilation. Induced vomiting is not recommended, due to the potential for CNS depression and seizures. To decrease absorption, administer activated charcoal as a slurry within 6 hours of ingestion. Activated charcoal, which may be used with sorbital, may be more effective than gastric lavage. Consider gastric lavage if it can be performed within 1 hour of ingestion. Protect airway by placement in the Trendelenburg and left lateral decubitus position or by endotracheal intubation. Control any seizures first. Use physostigmine, dihydroergotamine, angiotensin, or norepinephrine to counteract anticholinergic symptoms. Treat hypotension with isotonic fluid infusion. If hypotension persists, administer dopamine or norepinephrine and titrate to desired response. Do NOT use quinidine or procainamide to treat cardiac arrhythmias. For seizures, administer diazepam or lorazepam. Consider phenobarbital or propofol if seizures recur after diazepam. Monitor for elevated liver enzymes, granulocytopenia, tachycardia, antimuscarinic effects, hypotension, dysrhythmias, respiratory depression, and need for endotracheal intubation. Evaluate for hypoglycemia, electrolyte disturbances, and hypoxia. Monitor cardiac and vital signs, especially respiration, for several days because of possibly delayed effects. Provide assisted ventilation, if needed. Forced diuresis, dialysis, hemoperfusion, and exchange transfusion are not likely to be of benefit.

General information

Remove from exposure. Remove contaminated clothing. For treatment advice, seek guidance from an occupational health physician or other licensed health-care provider familiar with workplace chemical exposures. In the United States, the national poison control center phone number is 1-800-222-1222. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen if available. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention.

5. Fire-fighting measures

Suitable extinguishing media

Water. Foam. Dry chemical or CO2. Use fire-extinguishing media appropriate for surrounding

materials.

Unsuitable extinguishing media

None known.

Specific hazards arising from the chemical

Explosion hazard: Avoid generating dust; fine dust dispersed in air in sufficient concentrations and

Special protective equipment

in the presence of an ignition source is a potential dust explosion hazard.

and precautions for firefighters

Wear suitable protective equipment.

Fire fighting equipment/instructions As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.

Specific methods General fire hazards Use standard firefighting procedures and consider the hazards of other involved materials.

No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Keep unnecessary personnel away. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Avoid inhalation of dust from the spilled material. Wear appropriate protective equipment and clothing during clean-up. For personal protection, see section 8 of the SDS.

Material name: Clozapine USP SDS US Methods and materials for containment and cleaning up

Avoid the generation of dusts during clean-up. Sweep up or vacuum up spillage and collect in suitable container for disposal. Clean surface thoroughly to remove residual contamination. For waste disposal, see section 13 of the SDS.

Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly. Avoid significant deposits of material, especially on horizontal surfaces, which may become airborne and form combustible dust clouds and may contribute to secondary explosions. Combustible dust clouds may be created where operations produce fine material (dust). Select and use containment devices and personal protective equipment based on a risk assessment of material potency and exposure potential.

Conditions for safe storage, including any incompatibilities

Store in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

8. Exposure controls/personal protection

Occupational exposure limits

Exposure limit values

Industrial Use

 Material
 Type
 Value

 Clozapine (CAS 5786-21-0)
 TWA
 0.1 mg/m3

Biological limit values

No biological exposure limits noted for the ingredient(s).

Appropriate engineering controls

For laboratory operations, use local exhaust ventilation or a ventilated enclosure for high energy operations such as particle sizing. Control exposures to below the occupational exposure level (if available). Select and use containment devices and personal protective equipment based on a risk assessment of exposure potential. Cover all containers for solutions and slurries while being transferred.

Individual protection measures, such as personal protective equipment

Eye/face protection Wear safety glasses with side shields, chemical splash goggles, or full face shield, if necessary.

Base the choice of protection on the job activity and potential for contact with eyes or face. An

emergency eye wash station should be available.

Skin protection

Hand protection Wear nitrile or other impervious gloves if skin contact is possible. When the material is dissolved

or suspended in an organic solvent, wear gloves that provide protection against the solvent.

Other Train employees in proper gowning and degowning practices. Wear lab coat. Base the choice of

skin protection on the job activity, potential for skin contact and solvents and reagents in use. Do

not wear protective garments in common areas (e.g., cafeterias) or out-of-doors.

Respiratory protection Respirators are generally not required for laboratory operations. Use a tight-fitting full-face

respirator with HEPA filters for spill cleanup. Choose respiratory protection appropriate to the task

and the level of existing engineering controls.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

General hygiene considerations

Handling practices in this SDS are recommendations for laboratory use of reference standards.

Procedures for any other uses or quantities should be determined after an appropriate

assessment.

9. Physical and chemical properties

Appearance Appearance descriptions are general information and not specific to any USP lot.

Physical state Solid.
Form Powder.
Color Yellow.
Odor Not available.
PH Not available.
Not available.

Melting point/freezing point 359.6 - 366.8 °F (182 - 186 °C)

Initial boiling point and boiling Not available.

range

Flash point Not available.

Material name: Clozapine USP SDS US

Not available. **Evaporation rate** Not available. Flammability (solid, gas) Upper/lower flammability or explosive limits

(%)

Not available.

Flammability limit - upper

Flammability limit - lower

(%)

Not available.

Not available. Explosive limit - lower (%) Explosive limit - upper (%) Not available.

< 0.0000001 kPa at 25 °C Vapor pressure

Not available. Vapor density Not available. Relative density

Solubility(ies)

Solubility (water) Insoluble.

Acetone: Soluble. Solubility (other) Alcohol: Soluble.

Chloroform: Soluble.

Partition coefficient

(n-octanol/water)

3.23

Auto-ignition temperature > 680 °F (> 360 °C)

Decomposition temperature Not available. Not available. **Viscosity**

Other information

Chemical family Tricyclic dibenzodiazepine derivative.

Dust explosion properties

Minimum ignition energy (MIE) - dust

cloud

10 - 30 mJ

Molecular formula C18H19CIN4 Molecular weight 326.82

10. Stability and reactivity

Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

NOx. Cl-. Irritating and/or toxic fumes or gases. Emits toxic fumes under fire conditions.

11. Toxicological information

Information on likely routes of exposure

May cause drowsiness and dizziness. Inhalation

Knowledge about health hazard is incomplete. Skin contact Knowledge about health hazard is incomplete. Eye contact

Toxic if swallowed. Based on information from therapeutic use, this material may cause: Ingestion

Agranulocytosis.

Symptoms related to the

physical, chemical, and toxicological characteristics

Seizures. Central nervous system effects. Cardiovascular effects. Fever. Blurred vision. Weight

gain. Sweating. Gastrointestinal disturbances.

Information on toxicological effects

Acute toxicity Toxic if swallowed.

Material name: Clozapine USP SDS US Product Species Test Results

Clozapine (CAS 5786-21-0)

Oral

LD50 Rat 172 mg/kg

Skin corrosion/irritation Knowledge about health hazard is incomplete.

Serious eye damage/eye Knowledge about health hazard is incomplete.

irritation

Respiratory or skin sensitization

Respiratory sensitization
Skin sensitization
Knowledge about health hazard is incomplete.
Knowledge about health hazard is incomplete.
Knowledge about mutagenicity is incomplete.

Carcinogenicity Based on available data, the classification criteria are not met.

IARC Monographs. Overall Evaluation of Carcinogenicity

Not listed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)

Not regulated.

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

Reproductive toxicity Knowledge about health hazard is incomplete.

Reproductivity

40 mg/kg/day Reproductivity

Result: No fetal harm was observed in animals.

Specific target organ toxicity -

Narcotic effects.

single exposure

Specific target organ toxicity -

repeated exposure

Knowledge about health hazard is incomplete.

Aspiration hazard Based on available data, the classification criteria are not met.

Further information Pharmacologically active material. Occupational exposure may cause physiological effects.

12. Ecological information

Ecotoxicity The product is not classified as environmentally hazardous. However, this does not exclude the

No data is available on the degradability of this substance.

possibility that large or frequent spills can have a harmful or damaging effect on the environment.

Persistence and degradability

Bioaccumulative potential

Octanol/water partition coefficient log Kow

3.23

Mobility in soil No data available.

Other adverse effects No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation

potential, endocrine disruption, global warming potential) are expected from this component.

13. Disposal considerations

Disposal instructionsDispose in accordance with all applicable regulations. Under RCRA, it is the responsibility of the

user of the product to determine, at the time of disposal, whether the product meets RCRA criteria

for hazardous waste.

Local disposal regulations Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Waste from residues / unused

products

Empty containers or liners may retain some product residues. This material and its container must

be disposed of in a safe manner (see: Disposal instructions).

Contaminated packaging Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

DOT

UN number UN2811

UN proper shipping name Toxic solid, organic, n.o.s. (Clozapine)

Material name: Clozapine USP SDS US

Transport hazard class(es)

Class 6.1 Subsidiary risk -Packing group III

IATA

UN number UN2811

UN proper shipping name Toxic solid, organic, n.o.s. (Clozapine)

Transport hazard class(es)

Class 6.1
Subsidiary risk Packing group III
Other information

Passenger and cargo

aircraft

Allowed with restrictions.

Not applicable.

Cargo aircraft only Allowed with restrictions.

Transport in bulk according to Annex II of MARPOL 73/78 and

the IBC Code DOT; IATA



General information It is the shipper's responsibility to determine the correct transport classification at the time of

shipment.

15. Regulatory information

US federal regulations This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication

Standard, 29 CFR 1910.1200.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)

Not regulated.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous Yes

chemical

Classified hazard Combustible dust

categories Acute toxicity (any route of exposure)

Specific target organ toxicity (single or repeated exposure)

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Material name: Clozapine usp sps us

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

Not regulated.

(SDWA)

US state regulations

California Proposition 65



WARNING: This product can expose you to Clozapine, which is known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

California Proposition 65 - CRT: Listed date/Developmental toxin

Clozapine (CAS 5786-21-0) Listed: October 1, 1992

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	Yes
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	Yes
Philippines	Philippine Inventory of Chemicals and Chemical Substances	No

(PICCS)

Taiwan Chemical Substance Inventory (TCSI)

United States & Puerto Rico

Toxic Substances Control Act (TSCA) Inventory

No

16. Other information, including date of preparation or last revision

 Issue date
 06-17-2009

 Revision date
 05-29-2019

Version # 05

Further information Refer to NFPA 654, Standard for the Prevention of Fire and Dust Explosions from the

Manufacturing, Processing, and Handling of Combustible Particulate Solids, for safe handling.

Disclaimer USP Reference Standards are sold for chemical test and assay purposes only, and NOT for

human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information contained

herein.

Material name: Clozapine USP SDS US

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).